The following table presents the Company’s current pipeline: | | | | | | | | | | | | | Therapeutic Area | Name | Stage | Product Rights | | Cardiometabolic | ARO-APOC3 | Two Phase 2b and one Phase 3 | Arrowhead | | ARO-ANG3 | Two Phase 2b | Arrowhead | | Olpasiran | Phase 3 | Amgen | | Pulmonary | ARO-ENAC2 | Pre-Clinical | Arrowhead | | ARO-RAGE | Phase 1/2 | Arrowhead | | ARO-MUC5AC | Phase 1/2a | Arrowhead | | ARO-MMP7 | Phase 1/2 | Arrowhead | | Liver | ARO-HSD | Phase 1/2 | GSK | | ARO-AAT | Phase 2 | Takeda and Arrowhead | | JNJ-3989 | Phase 2 | Janssen | | ARO-XDH | Phase 1 | Horizon | | ARO-C3 | Phase 1/2 | Arrowhead | | JNJ-75220795 | Phase 1 | Janssen | | Muscle | ARO-DUX4 | Pre-Clinical | Arrowhead |
|